Brachytherapy
Volume 8, Issue 1 , Pages 45-51 , January 2009

Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy

  • Pirus Ghadjar

      Affiliations

    • Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland
    • ,
  • Tamara Keller

      Affiliations

    • Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland
    • ,
  • Cyrill A. Rentsch

      Affiliations

    • Department of Urology, University of Bern, Inselspital, Bern, Switzerland
    • ,
  • Bernhard Isaak

      Affiliations

    • Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland
    • ,
  • Frank Behrensmeier

      Affiliations

    • Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland
    • ,
  • Andrea Stroux

      Affiliations

    • Charité University Medicine Berlin, Institute for Biometry and Clinical Epidemiology, Berlin, Germany
    • ,
  • George N. Thalmann

      Affiliations

    • Department of Urology, University of Bern, Inselspital, Bern, Switzerland
    • ,
  • Daniel M. Aebersold

      Affiliations

    • Department of Radiation Oncology, University of Bern, Inselspital, Bern, Switzerland
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, University of Bern, Inselspital, Freiburgstrasse, 3011 Bern, Switzerland. Tel.: +41-31-632-2431; fax: +41-31-382-2342.

Received 11 June 2008 ,Revised 24 September 2008 ,Accepted 26 September 2008.

References 

  1. Bracarda S, de Cobelli O, Greco C, et al. Cancer of the prostate. Crit Rev Oncol Haematol. 2005;56:379–396
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;2006(56):106–130
  3. Ragde H, Korb LJ, Elgamaal A, et al. Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 2000;89:135–141
  4. Grimm PD, Blasko JC, Sylvester JE, et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  5. Eulau SM, Van Hollebeke L, Cavanagh W, et al. High dose rate iridium 192 brachytherapy in localized prostate cancer: Results and toxicity with maximum follow-up of 10 years. [Abstract] Int J Radiat Oncol Biol Phys. 2000;48(Suppl.):149
  6. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316–327
  7. Pellizzon AC, Nadalin W, Salvajoli JV, et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol. 2003;66:167–172
  8. Hiratsuka J, Jo Y, Yoshida K, et al. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:684–690
  9. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1048–1055
  10. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10 year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316
  11. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 2000;48:675–681
  12. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61–69
  13. Rodriguez RR, Demanes DJ, Altieri GA. High-dose-rate (HDR) monotherapy for early stage prostate cancer: preliminary results. [Abstract] Brachytherapy. 2003;2:62
  14. Martin T, Baltas D, Kurek R, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol. 2004;180:225–232
  15. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098–1104
  16. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys. 2003;56:213–220
  17. Yoshioka Y, Konishi K, Oh RJ, et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol. 2006;80:62–68
  18. Corner C, Rojas AM, Bryant L, et al. A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;[in press]
  19. Sobin LH, Wittekind CH. The prostate. In:  Sobin LH,  Wittekind CH editor. TNM Classification of Malignant Tumors. New York: Wiley-Liss; 2002;p. 184–187
  20. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  21. Brenner DJ, Hall EJ. Fractionation and protraction for radio-therapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  22. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679–694
  23. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116

PII: S1538-4721(08)00646-6

doi: 10.1016/j.brachy.2008.09.004

Brachytherapy
Volume 8, Issue 1 , Pages 45-51 , January 2009

Article Tools

* Image Usage & Resolution